Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Infrared light therapy hat for adults with drug-resistant epilepsy

Official title: An Open Label Pilot Study of Infrared Photobiomodulation in Humans With Epilepsy

Run by Beth Israel Deaconess Medical Center · NCT07145489 · Data updated 2026-11-12

This will try an infrared red-light therapy hat in adults with drug-resistant epilepsy to see if it reduces seizures and is comfortable to wear.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment13 (estimated)
SponsorBeth Israel Deaconess Medical Center
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedNovember 25, 2025
Main results expectedSeptember 25, 2026
Study endsSeptember 25, 2027
Registry record updatedFebruary 4, 2026
Trial IDNCT07145489 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with drug-resistant epilepsy who have an average of at least two seizures per month and maintain an accurate seizure diary are the intended candidates, provided they do not have excluded conditions like implanted intracranial devices or photosensitivity.

Probably not a fit

Patients with implanted intracranial neurostimulation devices, intracranial shunts, scalp cancer, known photosensitivity, or taking photosensitizing medications are excluded and are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human trial gives all participants an investigational Red Light Therapy Hat to test safety, tolerability, and effects on seizure frequency. The device has shown seizure-reducing effects in animal models but has not been tested for epilepsy in people. Participants must be adults with drug-resistant epilepsy who keep an accurate seizure diary and have at least two seizures per month; key exclusions include intracranial stimulators, shunts, scalp cancer, or photosensitivity. Study visits take place at Beth Israel Deaconess Medical Center and will monitor seizure counts and device tolerability over the treatment period.

Why it matters

Potential benefit: If successful, the device could reduce seizure frequency and offer a noninvasive treatment option for adults whose seizures do not respond to medications.

How similar studies have gone: Preclinical animal studies have suggested seizure reduction with infrared photobiomodulation, but its use for human epilepsy is novel and unproven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Drug resistant epilepsy
* Age 18 or older
* Average seizure rate of at least 2 seizures per month
* Accurate seizure diary with at least 3 months recorded

Exclusion Criteria:

* Implanted intracranial neurostimulation device (DBS or RNS)
* Intracranial shunt
* Skin photosensitivity
* Cancer on scalp
* Taking any medication that can cause photosensitivity

Where it's running

  • Bidmc
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.